Chronic Pancreatitis- From Inflammation to Fibrosis: Gastroenterology | May 2026

Article Type: Review — Basic and Clinical Gastroenterology & Hepatology

Introduction and Summary

Chronic pancreatitis is a progressive fibro-inflammatory disease characterised by recurrent or persistent abdominal pain, exocrine insufficiency, and eventual endocrine failure. Traditionally viewed as a structural disease diagnosed by ductal changes or calcification, it is now increasingly understood as a dynamic biological process beginning with acinar cell injury and evolving through inflammation to irreversible fibrosis.

This review highlights a critical gap in current practice: most patients are diagnosed at an advanced stage, when structural damage is already established, and therapeutic options are largely palliative. The authors emphasise the need to shift focus toward early disease mechanisms, particularly inflammation, and to develop therapies that can alter the natural course of the disease rather than simply manage its complications.

Problem Statement

The major challenge in chronic pancreatitis is not just treatment—it is late recognition and lack of disease-modifying therapy.

Early-stage disease remains difficult to diagnose due to the absence of validated biomarkers and limited access to histopathology. As a result, intervention typically occurs when fibrosis, ductal distortion, and calcification are already established.

Current treatment strategies—primarily endoscopic or surgical—focus on relieving ductal obstruction and managing pain. However, these approaches do not address the underlying inflammatory and fibrotic pathways driving disease progression.

This has limited progress in developing therapies that can prevent progression, reduce fibrosis, or preserve pancreatic function.

Key Concepts for Clinicians

1. Disease Begins with Acinar Cell Injury

Chronic pancreatitis starts with repeated or sustained injury to acinar cells, triggered by factors such as alcohol, smoking, genetic predisposition, or metabolic stress.

2. Inflammation Is the Central Driver

Following injury, a cascade of inflammatory responses is activated. Persistent inflammation leads to recruitment of immune cells and activation of pancreatic stellate cells.

3. Stellate Cells Drive Fibrosis

Activated stellate cells are central to fibrosis. They produce extracellular matrix components, leading to progressive replacement of normal pancreatic tissue with fibrotic tissue.

4. Progression Is a Continuum

The disease evolves from early inflammatory changes to late-stage fibrosis, ductal abnormalities, and calcification. Importantly, early stages may be reversible or modifiable, whereas late stages are largely irreversible.

5. Diagnosis Is Biased Toward Late Disease

Most diagnoses rely on imaging features such as ductal dilatation and calcification, which represent advanced disease. Early chronic pancreatitis remains underdiagnosed.

6. Lack of Biomarkers Limits Early Detection

There are no widely accepted biomarkers for early disease, making it difficult to identify patients at a stage where intervention could alter progression.

7. Current Therapies Are Mostly Symptomatic

Endoscopic and surgical interventions focus on ductal decompression and pain relief. They do not target the underlying inflammatory or fibrotic processes.

8. Disease-Modifying Therapy Is the Unmet Need

A major focus of research is identifying therapies that can interrupt inflammation, prevent stellate cell activation, and reduce fibrosis.

9. Emerging Therapies Target Pathophysiology

New strategies are exploring anti-inflammatory, anti-fibrotic, and antioxidant pathways. These include repurposed drugs and novel agents aimed at altering disease biology rather than structure.

10. Personalized Approach Is the Future

Given the heterogeneity of chronic pancreatitis, a patient-tailored strategy based on aetiology, stage, and dominant pathophysiological mechanism is essential.

Clinical Relevance

This review reinforces a paradigm shift: chronic pancreatitis should no longer be viewed purely as a structural disease requiring mechanical intervention, but as a biological disease driven by inflammation and fibrosis.

For clinicians, this means greater emphasis on:

Identifying patients at earlier stages

Recognising ongoing inflammation even in the absence of overt structural changes

Considering therapies that target disease mechanisms rather than only symptoms

It also supports ongoing efforts toward drug repurposing and translational research, particularly in targeting inflammation and fibrosis pathways.

Conclusion

Chronic pancreatitis is a progressive disease driven by a sequence of acinar injury, inflammation, and fibrosis. Current management remains focused on late-stage complications due to challenges in early diagnosis and a lack of effective disease-modifying therapies.

Future progress depends on improving early detection, understanding inflammatory pathways, and developing targeted treatments that can halt or reverse disease progression. A patient-tailored, mechanism-based approach represents the most promising direction for improving long-term outcomes.